Trends in Clinical Drug Trials for Type 2 Diabetes
Author Information
Author(s): Rakesh Parikh, Kirti Pandia, Mahesh Sharma, Meenakshi Dolima
Primary Institution: D Clinarch, Jaipur, India
Hypothesis
The study evaluates the trend of clinical drug trials in Type 2 diabetes mellitus over the last decade.
Conclusion
There has been a significant growth in drug trials for Type 2 diabetes from 2005 to 2008, but a plateau was observed afterward.
Supporting Evidence
- India and China contribute around 30% of the world's diabetic population but only a small percentage of clinical trials.
- USA, with a smaller percentage of the global diabetic population, conducted a significantly higher percentage of clinical trials.
Takeaway
The study looked at how many drug trials for diabetes have happened over the last ten years, showing that while many trials were done, not enough were from countries with a lot of diabetes patients.
Methodology
Data was obtained from the Clinical Drug Trials Registry of the USA, comparing the number of trials conducted in India, China, and the USA.
Potential Biases
The results may be biased due to the disproportionate representation of the USA in clinical trials.
Limitations
The study highlights a skew in representation of clinical trials, primarily from the USA, which may not reflect the diabetes populations in India and China.
Participant Demographics
The study focuses on diabetes populations in India, China, and the USA.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website